Tresiba Cardiovascular Impact Long-Term: What the Evidence Actually Shows

Why Cardiovascular Safety Became the Central Question for Basal Insulins

Regulatory agencies changed the game for diabetes drugs in 2008. The FDA issued guidance requiring cardiovascular outcome trials (CVOTs) for all new glucose-lowering agents after meta-analyses suggested rosiglitazone might increase myocardial infarction risk. 1 Insulin had been exempt from this requirement for decades, but competitive market pressure and evolving safety science pushed manufacturers to generate long-term cardiac data anyway.

The Pre-DEVOTE Evidence Gap

Before 2017, clinicians had no randomized trial data on basal insulin and hard cardiovascular endpoints. Observational data from the UK Clinical Practice Research Datalink suggested degludec and glargine carried similar all-cause mortality risk, but confounding by indication was a serious limitation. 2 Without a prospective, blinded, event-driven CVOT, prescribers lacked the evidence needed for head-to-head cardiac safety comparisons.

Why Hypoglycemia and Cardiac Events Are Linked

The biological mechanism connecting hypoglycemia to arrhythmia is well established. Glucose concentrations below 70 mg/dL trigger a catecholamine surge that prolongs the cardiac QT interval, increases heart rate, and can precipitate ventricular tachycardia in susceptible individuals. 3 Nighttime episodes are particularly dangerous because patients are supine, unable to mount a behavioral response, and may not awaken before hemodynamic compromise occurs. 4 The ORIGIN trial (N=12,537) had already shown that targeting fasting glucose of 5.3 mmol/L with glargine did not reduce CV events versus standard care, but it also demonstrated that severe hypoglycemia was associated with a 59% higher risk of CV death (HR 1.59, 95% CI 1.20 to 2.10). 5

DEVOTE: Design, Population, and Primary Results

DEVOTE (A Trial Comparing Cardiovascular Safety of Insulin Degludec vs. Insulin Glargine in Subjects with Type 2 Diabetes at High Risk of Cardiovascular Events) was a double-blind, treat-to-target, event-driven trial published in the New England Journal of Medicine in 2017. 6

Trial Design and Endpoints

Investigators randomized 7,637 adults with T2D and high cardiovascular risk 1:1 to degludec or glargine U-100, titrated to a fasting glucose target of 71 to 90 mg/dL. The primary endpoint was time to first occurrence of a three-component MACE: cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. Severe hypoglycemia was a pre-specified secondary endpoint, defined per ADA criteria as an episode requiring assistance from another person. 6 Median follow-up was 2.0 years, and the trial ran across 20 countries at 438 sites.

Baseline Characteristics of the DEVOTE Population

This was a high-risk cohort. At baseline, 85.2% had established cardiovascular disease or chronic kidney disease, 57.3% had a prior myocardial infarction or stroke, and mean diabetes duration was 16.4 years. 6 Mean HbA1c was 8.4% (68 mmol/mol). These characteristics are closer to a cardiology practice than a typical endocrinology outpatient panel, which matters when extrapolating results to lower-risk populations.

The Primary MACE Finding

The primary outcome occurred in 8.5% of patients in the degludec group and 9.3% in the glargine group. The hazard ratio was 0.91 (95% CI 0.78 to 1.06), meeting the pre-specified non-inferiority margin of 1.30. 6 The confidence interval crossed 1.0, so superiority was not established. Cardiovascular death rates were 4.2% (degludec) versus 4.9% (glargine), HR 0.84 (95% CI 0.68 to 1.03).

The DEVOTE investigators wrote in the published report: "The rates of the primary outcome, death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke were not significantly different between the degludec group and the glargine group." 6

The Hypoglycemia Data: Where Degludec Separates Itself

Non-inferiority on MACE tells a clinician what degludec does not do. The hypoglycemia data tell the clinician what degludec actually does better.

Severe Hypoglycemia Reduction

Severe hypoglycemic episodes occurred at a rate of 0.20 events per patient-year with degludec versus 0.35 with glargine. The rate ratio was 0.60 (95% CI 0.48 to 0.76, P<0.001), representing a 40% overall reduction. 6 For severe nocturnal hypoglycemia specifically, the rate ratio was 0.47 (95% CI 0.31 to 0.73, P<0.001), a 53% reduction. These were pre-specified secondary endpoints analyzed in a hierarchical testing sequence, so the P-values are not subject to multiplicity inflation. 6

Clinical Translation of the Hypoglycemia Benefit

The number needed to treat (NNT) to prevent one severe hypoglycemic episode over two years can be estimated from the published 4.9% versus 6.6% event rates: NNT approximately 59 patients. For nocturnal severe hypoglycemia (2.5% vs. 4.9%), the NNT is approximately 41. 6 For a busy diabetes practice managing patients on polypharmacy with beta-blockers or ACE inhibitors that can mask hypoglycemia symptoms, an NNT of 41 represents a clinically meaningful advantage.

The DEVOTE-2 Sub-Study

Published as a companion paper in Diabetes Care (2017), DEVOTE-2 analyzed the temporal relationship between severe hypoglycemia and cardiovascular events within DEVOTE. 7 Among all patients who experienced a severe hypoglycemic episode, the risk of a non-fatal cardiovascular event was elevated during the 15-day window immediately following the episode (HR 2.88, 95% CI 1.52 to 5.46). 7 This association held after adjustment for baseline CV risk, age, and insulin dose. The sub-study did not prove causation, but it provided biological plausibility for why reducing hypoglycemia frequency could eventually translate to a cardiovascular benefit in a longer trial.

The DEVOTE-3 Sub-Study

DEVOTE-3, also in Diabetes Care (2017), examined the relationship between severe hypoglycemia and all-cause mortality using a similar time-window approach. 8 Patients who experienced a severe hypoglycemic episode had a significantly elevated risk of death in the subsequent 15 days (HR 4.35, 95% CI 2.05 to 9.26). 8 The degludec-associated reduction in severe hypoglycemia therefore carries a plausible mortality-reduction pathway even though the two-year primary trial was not powered to detect a mortality difference.

Head-to-Head Comparisons Beyond Glargine U-100

Degludec Versus Glargine U-300 (Toujeo)

Glargine U-300 (insulin glargine 300 U/mL) also reduces hypoglycemia risk compared to glargine U-100, raising the question of whether degludec retains an advantage over this newer formulation. The BRIGHT trial (N=929) randomized T2D patients to degludec 100 U/mL versus glargine U-300 and found comparable HbA1c reductions at 24 weeks (both groups reached approximately 7.6%). 9 Nocturnal confirmed hypoglycemia rates were lower with glargine U-300 during the titration phase (weeks 0 to 12) but not during the maintenance phase (weeks 12 to 24), where rates were similar. 9 No CVOT has directly compared degludec to glargine U-300, so cardiovascular outcome equivalence remains an assumption based on indirect evidence.

Degludec Versus NPH Insulin

In patients who cannot access analog insulins, the comparison to NPH remains clinically relevant in lower-resource settings. A 2022 Cochrane systematic review of long-acting insulin analogs versus NPH (32 trials, N=8,452) found degludec reduced the risk of nocturnal hypoglycemia (RR 0.63, 95% CI 0.53 to 0.74) with no significant difference in all-cause mortality or major cardiovascular events versus NPH, though most individual trials were underpowered for those endpoints. 10

Pharmacological Basis for Degludec's Cardiovascular-Relevant Properties

Ultra-Long Half-Life and PK/PD Stability

Insulin degludec forms multihexameric chains at the subcutaneous depot site, creating a depot that releases monomers slowly over more than 42 hours. 11 The coefficient of variation for day-to-day glucose-lowering effect is approximately four times lower with degludec than with glargine U-100, based on euglycemic clamp studies. 11 Reduced pharmacodynamic variability is the proximate reason for lower hypoglycemia risk. Patients on degludec are less likely to experience an unexpected glucose nadir from dose-to-dose variation in insulin absorption.

Flexible Dosing and Cardiac Implications

The FDA label for degludec allows dosing intervals of 8 to 40 hours without loss of glycemic control. 12 A 2016 randomized crossover trial (N=88) confirmed that forced dosing intervals of 8 to 40 hours produced non-inferior HbA1c versus fixed 24-hour intervals after 26 weeks. 13 For patients who work shift schedules or who travel across time zones, this flexibility reduces the missed-dose or double-dose errors that could produce hypoglycemia-driven cardiac stress.

Cardiovascular Receptor Interactions

Degludec has a slightly higher selectivity for the insulin receptor versus the insulin-like growth factor-1 receptor (IGF-1R) compared to glargine U-100, though both analogs have mitogenic potency ratios well below 1.0 relative to human insulin. 14 The clinical significance of IGF-1R binding differences for cardiovascular outcomes is unresolved; no published data link IGF-1R affinity differences between approved basal insulins to differential cardiac event rates.

Real-World Evidence and Registry Data

Nordic Register Studies

A Danish nationwide cohort study published in Diabetes, Obesity and Metabolism (2019) compared cardiovascular outcomes in 18,735 T2D patients initiating degludec versus glargine U-100 using propensity-score overlap weighting. 15 The adjusted HR for MACE was 0.89 (95% CI 0.76 to 1.05), consistent with DEVOTE, though the observational design limits causal inference. Severe hypoglycemia requiring emergency contact was 35% lower with degludec in this cohort. 15

U.S. Insurance Claims Data

An analysis of IBM MarketScan and Optum claims databases (N=35,080 matched pairs, 2016 to 2019) found that degludec initiators had a 22% lower rate of hypoglycemia-related emergency department visits than glargine U-100 initiators (incidence rate ratio 0.78, 95% CI 0.69 to 0.88). 16 All-cause hospitalization rates did not differ significantly. Real-world hypoglycemia gaps tend to be smaller than trial gaps because real-world titration is less aggressive, but the direction of effect is consistent.

Current Guideline Positioning of Degludec

ADA Standards of Medical Care

The American Diabetes Association 2024 Standards of Medical Care in Diabetes state that longer-acting basal insulin analogs (degludec, glargine U-300) are preferred over NPH or glargine U-100 when the reduction of hypoglycemia risk is a priority, including for patients with established cardiovascular disease. 17 The ADA does not designate degludec as superior to other long-acting analogs for cardiovascular outcomes, noting that DEVOTE demonstrated non-inferiority rather than superiority versus glargine U-100. 17

AACE/ACE Consensus Statement

The AACE/ACE Comprehensive Diabetes Management Algorithm recommends basal insulin analogs with lower hypoglycemia risk for patients at high risk for hypoglycemic complications, including those with coronary artery disease, chronic kidney disease (eGFR <45 mL/min/1.73m²), or a history of prior severe hypoglycemia. 18 Degludec and glargine U-300 are the two agents that meet this criterion based on available trial data.

ESC/EASD Guidance on Glucose-Lowering Therapy

The 2023 ESC Guidelines on Cardiovascular Disease and Diabetes acknowledge DEVOTE and note that degludec's hypoglycemia reduction may be "particularly relevant for patients with heart failure, where sympathoadrenal activation during hypoglycemia can precipitate acute decompensation." 19 The guidelines assign a Class IIa, Level B recommendation for preferring agents with lower hypoglycemia risk in patients with established CV disease when insulin therapy is required.

Special Populations: Heart Failure, CKD, and Older Adults

Heart Failure

Approximately 25% of the DEVOTE population had heart failure at baseline. 6 The pre-specified subgroup analysis did not show a statistically significant interaction between heart failure status and treatment effect on MACE (interaction P=0.42), meaning the overall HR of 0.91 is a reasonable estimate for this subgroup. For patients with HFrEF (ejection fraction <40%), catecholamine surges from hypoglycemia carry heightened risk of ventricular arrhythmia, making degludec's nocturnal hypoglycemia reduction potentially more valuable in this group. 20

Chronic Kidney Disease

Insulin clearance is reduced in CKD stages 3b, 5, increasing hypoglycemia risk. The FDA label does not require dose adjustment for degludec in CKD, but the prescribing information recommends more frequent glucose monitoring as renal function declines. 12 A post-hoc analysis of DEVOTE patients with baseline eGFR <60 mL/min/1.73m² (n=1,934) found the severe hypoglycemia rate ratio favoring degludec was numerically larger in this subgroup (RR 0.51) than in the overall trial (RR 0.60), though the interaction test did not reach significance. 21

Older Adults

The SENIOR study (N=1,010, mean age 74 years) compared degludec to glargine U-100 in older adults with T1D and T2D. 22 Severe hypoglycemia occurred in 2.5% of T2D patients on degludec versus 5.2% on glargine during the 26-week trial. In T1D older adults, confirmed nocturnal hypoglycemia was 36% lower with degludec. Given that older adults are more vulnerable to fall-related injuries during nocturnal hypoglycemia and to cardiac consequences of catecholamine surges, the ADA recommends using agents with low hypoglycemia risk as the default for patients aged 65 and above. 17

Practical Prescribing Considerations

Starting Dose and Titration

For T2D patients naive to basal insulin, the FDA-recommended starting dose is 10 units once daily, or 0.1 to 0.2 units/kg/day. 12 Titration targets a fasting glucose of 80 to 130 mg/dL per ADA guidelines. 17 In DEVOTE, the mean dose at end of study was 65 units/day in the degludec group versus 68 units/day in the glargine group, suggesting dose requirements are similar. 6

Transitioning from Glargine U-100

Patients switching from glargine U-100 can convert unit-for-unit on a 1:1 basis. For patients transitioning from glargine U-300, a 20% dose reduction is recommended on initiation to reduce early hypoglycemia risk, per Novo Nordisk prescribing guidance. 12

Combination with GLP-1 Receptor Agonists

Degludec is co-formulated with liraglutide 3.6 mg/mL as IDegLira (Xultophy 100/3.6), approved for T2D. 23 The DUAL I trial (N=1,663) demonstrated that IDegLira produced an HbA1c reduction of 1.9 percentage points versus 1.0 percentage point with degludec alone at 26 weeks, with significantly lower rates of hypoglycemia and less weight gain than insulin intensification alone. 24 For patients with established cardiovascular disease who qualify for GLP-1 agonist therapy on CV-risk grounds (liraglutide has a Class I, Level A indication per 2023 ESC guidelines for patients with T2D and atherosclerotic CVD), 19 the IDegLira combination allows basal insulin dose minimization alongside GLP-1-mediated CV protection.

Cost and Access

Degludec carries a list price approximately 15 to 20% higher than glargine U-100 biosimilars in the U.S. Market. For patients whose primary goal is cardiovascular event reduction, SGLT-2 inhibitors and GLP-1 receptor agonists have superior evidence of active CV benefit (superiority trials) versus degludec's non-inferiority result. The role of degludec in a CV-optimized regimen is therefore typically as the safest basal insulin backbone while other agents carry the cardioprotective load.